Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $469.73 million. The enterprise value is $398.35 million.
| Market Cap | 469.73M |
| Enterprise Value | 398.35M |
Important Dates
The next estimated earnings date is Tuesday, November 17, 2026, before market open.
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 106.03 million shares outstanding. The number of shares has decreased by -1.16% in one year.
| Current Share Class | 106.03M |
| Shares Outstanding | 106.03M |
| Shares Change (YoY) | -1.16% |
| Shares Change (QoQ) | +10.14% |
| Owned by Insiders (%) | 5.74% |
| Owned by Institutions (%) | 8.23% |
| Float | 35.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.28 |
| Forward PS | 8.12 |
| PB Ratio | 4.36 |
| P/TBV Ratio | 4.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.26, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.26 |
| Quick Ratio | 3.59 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -17.44% and return on invested capital (ROIC) is -16.81%.
| Return on Equity (ROE) | -17.44% |
| Return on Assets (ROA) | -5.42% |
| Return on Invested Capital (ROIC) | -16.81% |
| Return on Capital Employed (ROCE) | -8.95% |
| Weighted Average Cost of Capital (WACC) | 30.07% |
| Revenue Per Employee | $175,709 |
| Profits Per Employee | -$31,853 |
| Employee Count | 625 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.67 |
Taxes
In the past 12 months, GYRE has paid $3.38 million in taxes.
| Income Tax | 3.38M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.81% in the last 52 weeks. The beta is 4.74, so GYRE's price volatility has been higher than the market average.
| Beta (5Y) | 4.74 |
| 52-Week Price Change | -39.81% |
| 50-Day Moving Average | 6.60 |
| 200-Day Moving Average | 6.94 |
| Relative Strength Index (RSI) | 30.11 |
| Average Volume (20 Days) | 163,121 |
Short Selling Information
The latest short interest is 1.93 million, so 1.82% of the outstanding shares have been sold short.
| Short Interest | 1.93M |
| Short Previous Month | 1.92M |
| Short % of Shares Out | 1.82% |
| Short % of Float | 5.36% |
| Short Ratio (days to cover) | 9.81 |
Income Statement
In the last 12 months, GYRE had revenue of $109.82 million and -$19.91 million in losses. Loss per share was -$0.22.
| Revenue | 109.82M |
| Gross Profit | 103.01M |
| Operating Income | -15.26M |
| Pretax Income | -22.29M |
| Net Income | -19.91M |
| EBITDA | -12.13M |
| EBIT | -15.26M |
| Loss Per Share | -$0.22 |
Balance Sheet
The company has $74.80 million in cash and $3.42 million in debt, with a net cash position of $71.38 million or $0.67 per share.
| Cash & Cash Equivalents | 74.80M |
| Total Debt | 3.42M |
| Net Cash | 71.38M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 164.92M |
| Book Value Per Share | 1.02 |
| Working Capital | 93.41M |
Cash Flow
In the last 12 months, operating cash flow was -$4.94 million and capital expenditures -$1.17 million, giving a free cash flow of -$6.11 million.
| Operating Cash Flow | -4.94M |
| Capital Expenditures | -1.17M |
| Depreciation & Amortization | 3.13M |
| Net Borrowing | n/a |
| Free Cash Flow | -6.11M |
| FCF Per Share | -$0.06 |
Margins
Gross margin is 93.80%, with operating and profit margins of -13.90% and -19.33%.
| Gross Margin | 93.80% |
| Operating Margin | -13.90% |
| Pretax Margin | -20.30% |
| Profit Margin | -19.33% |
| EBITDA Margin | -11.05% |
| EBIT Margin | -13.90% |
| FCF Margin | n/a |
Dividends & Yields
GYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.16% |
| Shareholder Yield | 1.16% |
| Earnings Yield | -4.89% |
| FCF Yield | -1.30% |
Analyst Forecast
The average price target for GYRE is $18.67, which is 321.45% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.67 |
| Price Target Difference | 321.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 55.25% |
| EPS Growth Forecast (3Y) | 119.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GYRE has an Altman Z-Score of 11.85 and a Piotroski F-Score of 1.
| Altman Z-Score | 11.85 |
| Piotroski F-Score | 1 |